Abstract: The present specification disclose polynucleotide molecules encoding an enterokinase, yeast expression constructs including a yeast expression vector and a polynucleotide molecules encoding an enterokinase, yeast cells comprising such a yeast expression construct, methods of producing enterokinase using such yeast cells, and method of cleaving or preparing a recombinant polypeptide using an enterokinase produced by such methods.
Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
Type:
Application
Filed:
March 13, 2013
Publication date:
October 10, 2013
Inventors:
Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Femandez-Salas
Abstract: The invention relates to commercially viable methods for producing biologically active vitamin K dependent proteins, particularly Factor IX. Factor IX is produced at a level of at least about 15 mg/L and is at least 25% biologically active. The method relies upon co-expression of one or more of paired basic amino acid converting enzyme (PACE), vitamin K dependent epoxide reductase (VKOR) and vitamin K dependent ?-glutamyl carboxylase (VKGC) at a preferred ratio so that the vitamin K dependent protein is efficiently produced and processed by a recombinant cell.
Type:
Application
Filed:
November 19, 2012
Publication date:
October 10, 2013
Inventors:
William N. Drohan, Michael J. Griffith, John R. Taylor, Darrell W. Stafford
Abstract: The invention relates to soluble rubella E1 antigens and variants of these antigens. The antigens contain amino acids 201 to 432 or 169 to 432 and are lacking amino acids 453 to 481 as well as at least the amino acids 143 to 164. They further contain a region spanning two disulfide-bridges. The invention also relates to a recombinant DNA molecule encoding the rubella E1 antigens, the expression of rubella E1 antigens as chaperone fusion proteins and their use in a method of detecting antibodies against rubella in a sample.
Type:
Grant
Filed:
June 3, 2010
Date of Patent:
October 8, 2013
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Christian Scholz, Ralf Bollhagen, Alfred Engel, Elke Faatz, Peter Schaarschmidt, Barbara Upmeier, Toralf Zarnt
Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.
Type:
Grant
Filed:
July 2, 2012
Date of Patent:
October 8, 2013
Assignees:
The Regents of the University of California, Schepens Eye Research Institute
Inventors:
Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
Abstract: The present invention relates to methods for producing variants of a parent TY145 subtilase and of a parent BPN? subtilase and to TY145 and BPN? variants having altered properties as compared to the parent TY145/BPN? subtilase.
Abstract: The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.
Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
Abstract: The present invention relates to a method for genetically modifying a filamentous fungus host for improved protein production. The method comprises that a filamentous fungus host is genetically modified to be deficient or to overexpress specific genes. The invention relates also to the modified hosts. Furthermore, the invention relates to a method for improved production or for producing an improved composition of proteins, such as cellulases, hemicellulases, other proteins involved in the degradation of lignocellulosic material, or other proteins, in a filamentous fungus host.
Type:
Application
Filed:
May 30, 2011
Publication date:
September 19, 2013
Applicant:
TEKNOLOGIAN TUTKIMUSKESKUS VTT
Inventors:
Tiina Pakula, Markku Saloheimo, Mari Hakkinen, Ann Westerholm-Parvinen, Merja Penttila, Marika Vitikainen
Abstract: The present invention provides a Bacillus sp. subtilisin variant. In addition, the present invention provides compositions comprising this serine protease variant. In some embodiments, the present invention provides laundry and other non-automatic (i.e., hand) dishwashing cleaning compositions comprising this serine protease variant.
Type:
Grant
Filed:
November 10, 2009
Date of Patent:
September 10, 2013
Assignee:
Danisco US Inc.
Inventors:
David A. Estell, Frits Goedegebuur, Ayrookaran Poulose
Abstract: Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote. One aspect relates to an isolated cell comprising the r-Antidote polynucleotide and Furin polynucleotide. Another aspect relates to a method for preparing the cleaved two-chain r-Antidote by expressing, in a cell, the pre-processed r-Antidote polypeptide and a Furin polypeptide.
Abstract: Provision of an anti-androgenic agent which has a strong anti-androgenic action, is free of side effects and very safe, and a sebum secretion blocker and a hair growth stimulant containing the anti-androgenic agent as an active ingredient. Provided are the anti-androgenic agent comprising lactoferrin, the sebum secretion blocker containing the anti-androgenic agent as an active ingredient, the hair growth stimulant containing the anti-androgenic agent as an active ingredient, and a food or drink product comprising the anti-androgenic agent containing lactoferrin as an active ingredient.
Type:
Application
Filed:
December 21, 2010
Publication date:
August 29, 2013
Inventors:
Yushi Kodama, Hiroaki Higuchi, Atsushi Narise, Koji Sakurai
Abstract: The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders.
Type:
Grant
Filed:
January 2, 2013
Date of Patent:
August 27, 2013
Assignee:
Institut National de la Sante et de la Recherche Medicale (INSERM)
Inventors:
Olivier Christophe, Cecile Denis, Ghislaine Cherel, Paul Gueguen
Abstract: A food composition comprising a hydrophobin, a protein and/or polysaccharide and a corresponding denaturing enzyme is provided, wherein the activity of the denaturing enzyme has been substantially reduced.
Abstract: An enzyme solution for separating cell(s) which can lessen damage in separating a single cell or a mass of cells from a tissue or an organ, a method for separating cell(s) using the enzyme solution, and a method for separating pancreatic islet(s) using the enzyme solution. The enzyme solution for separating cell(s) is an enzyme solution containing a chloride ion channel inhibitor or having a chloride ion concentration of 10 mM or lower. By an enzymatic treatment using the enzyme solution for separating cell(s), a single cell or a mass of cells can be separated from a tissue or an organ. To separate pancreatic islet(s) from the pancreas, the enzyme is injected through the pancreatic duct to digest the pancreas.
Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
Type:
Grant
Filed:
May 20, 2011
Date of Patent:
August 20, 2013
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
Abstract: Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.
Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.
Type:
Grant
Filed:
October 23, 2009
Date of Patent:
August 13, 2013
Assignees:
The Regents of the University of California, Schepens Eye Research Institute
Inventors:
Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
Abstract: The present invention features inter alia nucleic acid molecules which encode polypeptides comprising a single chain Fc region and the polypeptides they encode. The Fc moieties of these constructs are linked by a cleavable scFc linker which is adjacent to at least one enzymatic cleavage site, e.g., an intracellular processing site. The resulting processed molecules comprise two polypeptide chains and substantially lack the extraneous amino acid sequence found in single chain Fc linker molecule. Methods of making and using these dimeric molecules are also described.
Abstract: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
Type:
Grant
Filed:
March 5, 2010
Date of Patent:
August 6, 2013
Assignee:
Vertex Pharmaceuticals Incorporated
Inventors:
Chao Lin, Tara Kieffer, Christoph Sarrazin, Ann Kwong
Abstract: This invention relates to methods of treating Alzheimer's disease or symptoms thereof, and amnesic mild cognitive impairment or symptoms thereof. Methods of the invention include administering a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof. The invention further relates to uses of tissue kallikrein or a variant or active fragment thereof for the digesting or cleaving amyloid and the treatment of conditions benefiting from the digestion or cleavage of amyloid. The invention further relates to pharmaceutical compositions comprising a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof formulated for oral or intranasal administration.
Abstract: An object of the present invention is to provide a method for efficiently producing an oligomer or a monomer by degrading a biodegradable resin using an enzyme, so that the oligomer or the monomer can be recovered. The present invention provides a method for producing an oligomer and/or a monomer by degrading a biodegradable resin in a degradation liquid containing a biodegradation enzyme, a buffer agent, an organic solvent, and water. In this method, the SP value of the organic solvent is less than 8.5 or more than 11.5, and the percentage content of the organic solvent (by volume) in the degradation liquid is higher than 1% and lower than 15%. In the method for producing an oligomer or a monomer, the degradation percentage of the biodegradable resin is low, and deposits of aggregates of the oligomer and/or the monomer are few, so that the recovery percentage is high.
Abstract: The present invention relates to potato virus NIa protease variants or fragments thereof, polynucleotides encoding them, and methods of making and using the foregoing.
Type:
Application
Filed:
March 22, 2013
Publication date:
August 1, 2013
Applicant:
CENTOCOR ORTHO BIOTECH INC.
Inventors:
Ellen Chi, Michael Hunter, Ronald Swanson
Abstract: The present invention concerns a recombinant or transgenic factor VII compound, each factor VII molecule of the compound having glycan forms linked to N-glycosylation sites, wherein among all the factor VII molecules in said compound, glycan, biantennary, bisialylated and non-fucosylated forms are in the majority. The invention also concerns such a compound for use as a medication, and a method for preparing said compound, among others.
Abstract: [PROBLEMS TO BE SOLVED] It is an object of the present invention to provide a gelator containing a long chain oxyaminopolyol capable of forming a gel with a small amount thereof over a liquid property range from acidic to alkaline, and a gel having high environmental suitability, biocompatibility and biodegradability. [MEANS FOR SOLVING THE PROBLEMS] A gelator, characterized by containing a long chain oxyaminopolyol of Formula (I): (where R1 is a C12-16 saturated aliphatic group or a C12-16 unsaturated aliphatic group having one double bond; R2 is a substituent which an amino acid has; and X is an oxygen atom or NH) and a pharmaceutically acceptable salt thereof; a self-assembly formed by the self-assembly of the gelator; and a gel containing the gelator or the self-assembly, and water, an aqueous solution, a hydrophilic organic solvent or a hydrophilic organic solution, or a hydrophobic organic solvent or a hydrophobic organic solution.
Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
Abstract: Provided herein are compositions and methods for inhibiting viral infection of a host cell. The methods comprise contacting the the host cell with an effective amount of one or more polypeptides having a disintegrin domain. The polypeptide can be CN, VCN or modified ADAM-derived polypeptide (MAP), or a fusion protein comprising a CN, VCN or MAP.
Type:
Application
Filed:
November 12, 2012
Publication date:
July 11, 2013
Applicants:
WESTERN UNIVERSITY OF HEALTH SCIENCES, UNIVERSITY OF SOUTHERN CALIFORNIA
Inventors:
University of Southern California, Western University of Health Sciences
Abstract: Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases.
Abstract: The present invention provides a mutant 27 kDa NIa proteinase having reduced self-cleavage activity relative to the self-cleavage activity of its wild-type proteinase. The mutant has the same substrate cleavage activity as the wild-type proteinase but is more stable than the wild-type proteinase. The present invention also provides a method of obtaining large quantities of active 27 kDa NIa proteinase for use as a tool for purification of other proteins.
Type:
Grant
Filed:
May 29, 2012
Date of Patent:
June 25, 2013
Assignee:
Yale University
Inventors:
Jennifer A. Doudna, Louise J. Lucast, Robert T. Batey
Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.
Type:
Application
Filed:
November 26, 2012
Publication date:
June 20, 2013
Applicant:
University of Pittsburgh-Of the Commonwealth System of Higher Education
Inventor:
University of pittsburgh-of the commonwealth syst
Abstract: The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample.
Abstract: A biomarker, method, test kit, and diagnostic system for detecting the presence of lymphoma in a person are disclosed. The lymphoma may be Hodgkin's lymphoma or non-Hodgkin's lymphoma. The person may be a high-risk subject. In one embodiment, a plasma sample from a person is obtained. The level of at least one protein listed in Table S3 in the plasma sample is measured. The level of at least one protein in the plasma sample is compared with the level in a normal or healthy subject. The lymphoma is diagnosed based upon the level of the at least one protein in the plasma sample in comparison to the normal or healthy level.
Abstract: This invention provides information on differentially expressed genes in malignant tissue of gastric, colon and pancreatic adenocarcinomas as compared to their corresponding adjacent non-malignant tissues. These genes or their products can be used as targets in developing new strategies for the treatment and diagnosis of these gastrointestinal cancers.
Type:
Application
Filed:
August 10, 2011
Publication date:
May 23, 2013
Applicant:
CTI Salud S.A.
Inventors:
Manuel Gidekel, Carolina Del Carmen Bizama Soto, Felipe Mario Benavente Muñoz, Hieda Ana Gutievez Moraga, Osvaldo Luis Podhajcer, Edgardo Enrique Salvatierra Colussi, Guiller Mo Daniel Mazzolini, Juan Carlos Roa
Abstract: The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production ia mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.
Type:
Grant
Filed:
June 16, 2004
Date of Patent:
May 14, 2013
Assignee:
Nordmark Arzneimittel GmbH & Co. KG
Inventors:
Manfred Kurfürst, Christian Raemsch, Nicole Raemsch-Guenther, Olaf Friedrich, Silke Huettler, Daniel Brandhorst, Thierry Berney, Pascal Bucher, Heide Brandhorst
Abstract: The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.
Abstract: The present: invention reveals a strong correlation between FGL-2 prothrombinase activity levels and the presence of a malignant proliferative disorder in a subject. Thus, the present invention provides FGL-2 prothrombinase activity as a diagnostic tool for malignancy.
Type:
Application
Filed:
July 11, 2011
Publication date:
May 9, 2013
Applicants:
RAMOT AT TEL-AVIV UNIVERSITY LTD., MOR RESEARCH APPLICATIONS LTD.
Abstract: The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders.
Type:
Grant
Filed:
December 21, 2009
Date of Patent:
May 7, 2013
Assignee:
Institut National de la Sante et de la Recherche Medicale (INSERM)
Inventors:
Olivier Christophe, Cecile Denis, Ghislaine Cherel, Paul Gueguen
Abstract: Provided are methods and compositions for detecting a compound that activates a sirtuin deacetylase activity on a fluorescent-free activation substrate in vitro. Further provided are sirtuin modulating compounds of the formulas (I)-(XXI), and related compounds (XXXI), (XXXII), (XXXIII), and (XXXIV), including the fluorescent free-substrate SIRT1 activator compounds of formulas (XL), (XI), (XII), and (XIII).
Type:
Application
Filed:
April 15, 2011
Publication date:
April 25, 2013
Inventors:
Han Dai, Thomas V. Riera, Ross L. Stein, Bruce Szczepankiewicz
Abstract: The present invention relates to pharmaceutical compositions containing lactoferrin, or fragments of it, and their use in the treatment of wounds, particularly corneal wounds. The present invention also provides a pharmaceutical composition comprising an effective amount of a polypeptide or peptidomimetic consisting essentially of the C-lobe of lactoferrin, or functionally active fragments or variants thereof.
Type:
Application
Filed:
July 1, 2011
Publication date:
April 25, 2013
Applicant:
Brien Holden Vision Institute
Inventors:
Benjamin David Ashby, Qian Garrett, Mark Willcox
Abstract: The present invention relates to potato virus NIa protease variants or fragments thereof, polynucleotides encoding them, and methods of making and using the foregoing.
Type:
Grant
Filed:
April 14, 2011
Date of Patent:
April 23, 2013
Assignee:
Centocor Ortho Biotech Inc.
Inventors:
Ellen Chi, Michael Hunter, Ronald Swanson
Abstract: The present invention relates to isolated polynucleotides having leader sequence function. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods using the polynucleotides for production of polypeptides.
Abstract: A therapeutic composition for the treatment of the symptoms of complex regional pain syndrome and a method for preparing the therapeutic composition is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of complex regional pain syndrome, or the likelihood of an individual to develop complex regional pain syndrome is disclosed.
Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.
Abstract: Promoter regions associated with the Yarrowia lipolytica peroxisomal 2,4-dienoyl-CoA reductase (SPS19) gene are disclosed and have been found to be particularly effective for the expression of heterologous genes in yeast. These promoter regions will be useful for driving high-level expression of genes involved in the production of omega-3 and omega-6 fatty acids.
Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors.
Type:
Application
Filed:
March 21, 2011
Publication date:
April 11, 2013
Applicant:
LIFENET HEALTH
Inventors:
Xiaofei Qin, Silvia Chen, Jingsong Chen, James A. Clagett
Abstract: The present invention relates to isolated polynucleotides having promoter activity the juse of the isolated polynucleotides for the procuction of a polypeptide. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing a desired polypeptide using the polypeptide having promoter activity.
Abstract: A protease for treating nail abnormalities is a type of protease. Since nails are mostly composed of keratin protein, the optimum protease for decomposing the main component (keratin) of the nail is keratinase or serine protease which is functionally similar to keratinase. The serine protease include trypsin, chymotrypsin, elastase, subtilisin, etc, these enzymes can be used to treat pathologically or mechanically damaged nail tissue to thin or remove keratin which is the key component of the nail, thus facilitating drug delivery in later treatment.
Abstract: The present invention relates a host cell comprising an expression vector comprising a nucleic acid molecule encoding a protein requiring gamma-carboxylation and associated expression control sequences and a nucleic acid molecule encoding a vitamin K epoxido reductase and associated expression control sequences and a nucleic acid molecule encoding a ?-glutamyl carboxylase and associated control sequences. The invention further relates to a method of producing a protein requiring gamma-carboxylation in high yields.
Abstract: The invention relates to a method of modifying a specific lysine residue in a polypeptide comprising at least two lysine residues, said method comprising (a) providing a polypeptide comprising a target lysine residue protected by a first protecting group, and at least one further lysine residue; (b) treating the polypeptide to protect said further lysine residue(s), wherein the protecting group for said further lysine residues is different to the protecting group for the target lysine residue; (c) selectively deprotecting the target lysine residue; and (d) modifying the deprotected lysine residue of (c).
Abstract: The present invention provides a universally applicable lysis buffer comprising a chaotropic 5 agent, a reducing agent, and a proteolytic enzyme suitable for processing a wide variety o different sample types, such as different types of bodily samples relevant for the diagnosis o a respiratory disease. Furthermore, the present invention provides the use of a chaotropic agent, a reducing agent, and a proteolytic enzyme for the lysis of a broad spectrum of bodily samples. Moreover, the present invention provides a method for processing bodily samples which is universally applicable to the lysis of a variety of different types of bodily samples. Furthermore, the present invention provides methods for analyzing a bodily sample or for detecting the presence of a pathogen in a bodily sample, preferably, for diagnosing a respiratory disease, such as pneumonia or tuberculosis.
Type:
Application
Filed:
May 9, 2011
Publication date:
March 14, 2013
Applicant:
CURETIS AG
Inventors:
Matthias Klein, Gerd Lüdke, Andreas Boos